

## Accepted Manuscript

Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents

Konstantina Karypidou, Sergio R. Ribone, Mario A. Quevedo, Leentje Persoons, Christophe Pannecouque, Christine Helsen, Frank Claessens, Wim Dehaen

PII: S0960-894X(18)30750-9  
DOI: <https://doi.org/10.1016/j.bmcl.2018.09.019>  
Reference: BMCL 26040

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 25 July 2018  
Revised Date: 11 September 2018  
Accepted Date: 15 September 2018

Please cite this article as: Karypidou, K., Ribone, S.R., Quevedo, M.A., Persoons, L., Pannecouque, C., Helsen, C., Claessens, F., Dehaen, W., Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents, *Bioorganic & Medicinal Chemistry Letters* (2018), doi: <https://doi.org/10.1016/j.bmcl.2018.09.019>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents

Konstantina Karypidou<sup>a</sup>, Sergio R. Ribone<sup>b</sup>, Mario A. Quevedo<sup>b</sup>, Leentje Persoons<sup>c</sup>, Christophe Pannecouque<sup>c</sup>,  
Christine Helsen<sup>d</sup>, Frank Claessens<sup>d</sup> and Wim Dehaen<sup>a\*</sup>

<sup>a</sup> Molecular Design and Synthesis, Department of Chemistry, KU Leuven, Celestijnenlaan 200F, 3001, Leuven, Belgium

\*[wim.dehaen@kuleuven.be](mailto:wim.dehaen@kuleuven.be), [konstantina.karypidou@kuleuven.be](mailto:konstantina.karypidou@kuleuven.be),

<sup>b</sup> Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA, CONICET), Dpto. Farmacia, Fac. Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, X5000HUA, Argentina  
[alfredoq@fcq.unc.edu.ar](mailto:alfredoq@fcq.unc.edu.ar), [sribone@fcq.unc.edu.ar](mailto:sribone@fcq.unc.edu.ar)

<sup>c</sup> Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium  
[christophe.pannecouque@kuleuven.be](mailto:christophe.pannecouque@kuleuven.be), [leentje.persoons@kuleuven.be](mailto:leentje.persoons@kuleuven.be)

<sup>d</sup> Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium  
[frank.claessens@kuleuven.be](mailto:frank.claessens@kuleuven.be), [christine.helsen@kuleuven.be](mailto:christine.helsen@kuleuven.be)

## Abstract

Synthesis and biological evaluation of a novel library of fused 1,2,3-triazole derivatives are described. **The in-house developed** multicomponent reaction based on commercially available starting materials was applied and broad biological screening against various viruses was performed, showing promising antiviral properties for compounds **14d**, **14n**, **14q**, **18f** and **18i** against human coronavirus 229E. Further *in silico* studies identified the key molecular interactions between those compounds and the 3-chymotrypsin-like protease, which is essential to the intracellular replication of the virus, supporting the hypothesis that the protease is the target molecule of the potential antiviral derivatives.

Keywords: Respiratory Syndrome, Coronavirus, 3CL protease, 1,2,3-triazole, biological evaluation

Coronaviruses are single-stranded RNA viruses associated with mild to severe respiratory symptoms. Human coronaviruses (HCoV) strains HCoV-229E and HCoV-OC43 were first described in the 1960s as causes for respiratory tract infections in humans, including common cold and pneumonia.<sup>1</sup> In 2002-2003, a new human coronavirus, named SARS-CoV, was identified as the etiological agent for the global outbreak of severe acute respiratory syndrome (SARS), which caused the death of over 800 individuals among 8000 cases worldwide, representing a fatality rate of almost 10%.<sup>2,3,4</sup> Since then three additional coronaviruses have been recognized. Initially, HCoV-NL63<sup>5</sup> and HCoV-HKU1,<sup>6</sup> were reported causing acute respiratory diseases of lower severity compared to the SARS-CoV and more recently, Middle East respiratory syndrome (MERS-CoV) causing lethal respiratory diseases.<sup>7,8</sup> To date, there are no approved antiviral drugs or vaccines available for the prevention and/or treatment of SARS-like viruses making the development of effective antiviral agents an imperative need.<sup>9</sup>

Coronaviruses express two proteases, a papain-like protease (PL<sup>pro</sup>) and a 3-chymotrypsin-like protease (3CL<sup>pro</sup>). The 3CL<sup>pro</sup> enzyme, also referred to as Main protease (M<sup>pro</sup>), is essential to the intracellular viral replication, making it an attractive target for the development of novel inhibitors.<sup>10</sup> Reports in the literature

Download English Version:

<https://daneshyari.com/en/article/11011579>

Download Persian Version:

<https://daneshyari.com/article/11011579>

[Daneshyari.com](https://daneshyari.com)